Safety information / evidence gaps
Selank
FDA identifies important gaps in safety information for selank acetate.
No dosing or purchase guidance. This information is not a recommendation to use a compound.
Keep the safety limits visible.
The FDA entry is for selank acetate, also called TP-7. It describes potential immunogenicity risks for certain routes because of aggregation and peptide-related impurities.
FDA says it lacks important information about safety issues raised by administering selank acetate to humans. This gap is not evidence that a product is safe.
This source does not establish an anxiety-treatment or cognitive-enhancement benefit. Product identity and route must be checked separately. No dose, medical advice or purchase guidance is provided.
Original source
Interpretation is limited to the source linked above. Independent medical review pending.